Abstract

EMERGING TRENDS AND CHALLENGES IN NANOPARTICLE- BASED DRUG DELIVERY SYSTEMS FOR TARGETED CANCER THERAPY

Priti K. Mathpati*, Shrihari B. Ghule, Karishma Y. Maneri, Kailas R. Jadhav, Pradnya H. Gadhire, Sanjay K. Bais

ABSTRACT

Nanoparticle-based drug delivery systems are changing how we treat cancer by targeting tumors more precisely. They release drugs right where needed, which cuts down on side effects for the whole body. Plus, they help get past things like when tumors resist multiple drugs. This seems like a big deal for targeted therapy. I mean, from what Ive read in recent stuff, between 2024 and 2026, there are these new nanoparticles that respond to stimuli. They activate based on the environment around the tumor or something. And then there are hybrids that mix in gene therapy or even immunotherapy. For cancers like breast or lung, that could make treatments work better overall. But translating this to actual patients is tough. Even though preclinical tests look good, scaling up production is a hassle. Reproducibility in manufacturing does not always happen smoothly. And regulatory hurdles for these complex setups area real barrier. Future stuff might help though. Like combining different regimens or using AI to optimize designs. That could push these systems faster from lab to clinic. It feels like they could have a wider impact on cancer care, but Im not totally sure how quickly that will play out. Some people think its promising, others worry about the challenges piling up.

Keywords: Drug delivery methods, tumor microenvironment, multidrug resistance, immunotherapy combination, stimuli-responsive nanoparticles, targeted cancer therapy, and clinical translation.